A5024502000- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Mosquito-borne diseases and control
- Animal Virus Infections Studies
- Immunotherapy and Immune Responses
- Viral Infections and Vectors
- vaccines and immunoinformatics approaches
- Viral Infections and Immunology Research
- Peripheral Neuropathies and Disorders
- Long-Term Effects of COVID-19
- Heparin-Induced Thrombocytopenia and Thrombosis
- HIV Research and Treatment
- Respiratory viral infections research
- Viral Infections and Outbreaks Research
- Vaccine Coverage and Hesitancy
- Multiple Sclerosis Research Studies
- Virology and Viral Diseases
- Vibrio bacteria research studies
- Malaria Research and Control
- Plant Virus Research Studies
Medical University of Vienna
2017-2024
Evidence suggests that B cell-depleting therapy with rituximab (RTX) affects humoral immune response after vaccination. It remains unclear whether RTX-treated patients can develop a and T-cell-mediated against SARS-CoV-2 immunisation.Patients under RTX treatment (n=74) were vaccinated twice either mRNA-1273 or BNT162b2. Antibodies quantified using the Elecsys Anti-SARS-CoV-2 S immunoassay receptor-binding domain (RBD) of spike protein neutralisation tests. SARS-CoV-2-specific T-cell...
CD8+ T cell immunity to SARS-CoV-2 has been implicated in COVID-19 severity and virus control. Here, we identified nonsynonymous mutations MHC-I-restricted epitopes after deep sequencing of 747 isolates. Mutant peptides exhibited diminished or abrogated MHC-I binding a cell-free vitro assay. Reduced mutant was associated with decreased proliferation, IFN-γ production cytotoxic activity cells isolated from HLA-matched patients. Single RNA ex vivo expanded, tetramer-sorted patients further...
Fewer than 50% of kidney transplant recipients (KTRs) develop antibodies against the SARS-CoV-2 spike protein after 2 doses an mRNA vaccine. Preliminary data suggest that a heterologous vaccination, combining and viral vector vaccines, may increase immunogenicity.To assess effectiveness third dose vs vaccine in KTRs who did not have vaccine.This was single center, single-blinded, 1:1 randomized clinical trial SARS-CoV-2, conducted from June 15 to August 16, 2021, 201 had developed Data...
SARS-CoV-2-induced COVID-19 has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond conventional vaccination.In this blinded randomised clinical trial, we compare the efficacy and safety of an additional booster vaccination with a vector versus mRNA vaccine non-seroconverted patients. We assigned 60 patients under rituximab treatment, did not seroconvert after their primary either BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna),...
Disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from mild illness to disease and death. In this study, we determined kinetics of viral loads, antibody responses (IgM, IgG, neutralization) SARS-CoV-2-specific CD4 T cells quantifying these parameters in 435 serial blood samples collected a cohort 29 COVID-19 patients with either moderate or during whole period hospitalization until Remarkably, there was no significant difference plateau levels...
Objective The study was undertaken to assess the impact of B cell depletion on humoral and cellular immune responses severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccination in patients with various neuroimmunologic disorders anti‐CD20 therapy. This included an analysis T vaccine response SARS‐CoV‐2 Delta variant. Methods We investigated prospectively mRNA 82 therapy age‐ sex‐matched healthy controls. For quantification antibodies, Elecsys anti‐SARS‐CoV‐2 viral spike (S)...
Patients under rituximab therapy are at high risk for a severe COVID-19 disease course. Humoral immune responses to SARS-CoV-2 vaccination vastly diminished in B-cell-depleted patients, even after third vaccine dose. However, it remains unclear whether these patients benefit from fourth and continued affects antibody development.In this open-label extension trial, 37 rituximab-treated who received dose with either vector or mRNA-based were vaccinated time an (mRNA-1273 BNT162b2). Key...
Impaired response to COVID-19 vaccination is of particular concern in immunosuppressed patients. To determine the best strategy for this vulnerable group we performed a single center, 1:1 randomized blinded clinical trial. Patients who failed seroconvert upon two mRNA vaccinations (BNT162b2 or mRNA-1273) are receive either third dose same vector vaccine ChAdOx1 nCoV-19. Primary endpoint difference SARS-CoV-2 spike antibody seroconversion rate between and vaccinated patients four weeks after...
Zika virus has recently caused explosive outbreaks in Pacific islands, South- and Central America. Like with other flaviviruses, protective immunity is strongly dependent on potently neutralizing antibodies directed against the viral envelope protein E. Such antibody formation promoted by CD4 T cells through direct interaction B that present epitopes derived from E or structural proteins of virus. Here we examined extent epitope dominance cell responses to capsid (C) patients. All patients...
The ubiquitous Torque teno virus (TTV) establishes a chronically persistent infection in the human host. TTV has not been associated with any apparent disease, but, as part of virome, it may confer regulatory imprint on immune system yet unclear consequences. However, so far, only few studies have characterized TTV-specific responses or overall immunological imprints by TTV. Here, we reveal that leads to highly exhausted CD8
ABSTRACT Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond conventional COVID-19 vaccination. In this blinded randomized clinical trial (EudraCT 2021-002348-57) we compare the efficacy and safety of an additional booster vaccination with a vector versus mRNA vaccine non-seroconverted patients. We assigned 60 patients under...
The live attenuated yellow fever (YF) vaccine is a highly effective human and induces long-term protective neutralizing antibodies directed against the viral envelope protein E. generation of such requires help CD4 T cells which recognize peptides derived from proteins in virus particles internalized processed by E-specific B cells. helper cell response restricted to few immunodominant epitopes, but mechanisms their selection are largely unknown. Here, we report that responses elicited...
Abstract CD8+ T cell immunity to SARS-CoV-2 has been implicated in COVID-19 severity and virus control, though direct evidence lacking so far. Here, we identified non-synonymous mutations MHC-I restricted epitopes after deep sequencing of 747 SARS-CoV- 2 isolates. Mutant peptides exhibited diminished or abrogated binding, which was associated with a loss recognition functional responses by cells isolated from HLA-matched patients. Our findings highlight the capacity subvert surveillance...
Here we analyzed SARS-CoV-2-specific antibodies and T-cell responses after two coronavirus disease 2019 vaccinations over a six-month period in patients with hematological malignancies assessed the effect of third vaccination subgroup. Sixty-six 66 healthy controls were included. After seroconversion was seen 52% T-cell-specific response 59% compared 100% (p = 0.001). Risk factors for poor serological age (<65a), history anti-CD20 therapy within year preceding vaccination, CD19+ B-cells <...
This prospective cohort study analyzed the immune response to COVID-19 mRNA vaccines in lung transplant recipients (LuTRs) compared healthy controls (HCs) at a 6-month follow-up.After first two doses of either BNT162b2 or mRNA-1273, SARS-CoV-2 antibodies were measured LuTRs (n = 57) and sex- age-matched HCs 57). Antibody kinetics during follow-up effect third vaccine dose evaluated. Humoral responses assessed using Elecsys® Anti-SARS-CoV-2 S immunoassay. In 16 LuTRs, SARS-CoV-2-specific T...
West Nile (WN) virus infection of humans is frequently asymptomatic, but can also lead to WN fever or neuroinvasive disease. CD4 T cells and B are critical in the defence against virus, neutralizing antibodies, which directed viral glycoprotein E, an accepted correlate protection. For efficient production these interact directly with helper that recognize peptides from E two other structural proteins (capsid-C membrane-prM/M) virus. However, specific protein sites yielding such epitopes...
Solid organ transplant recipients (SOTRs) are considered to be at high risk for severe complications and even death when infected with COVID-19. 1 In heart (HTRs), COVID-19 is associated a mortality rate of up 25%. 2 Yet, some recently published data indicate similar safety profile but reduced immune responses mRNA vaccine in SOTRs compared from immunocompetent persons. 3e the humoral cellular after administration two doses vaccines (HTRs) against health controls (healthcare workers Medical...
Background: Patients with neuroimmunological disorders on anti-CD20 therapy are at increased risk of severe COVID-19. However, little is known about SARS-CoV-2 vaccine efficacy in this cohort. In particular, the impact B cell depletion humoral and cellular immune responses to vaccination remains poorly defined. No study has addressed delta variant immunocompromised individuals so far.Methods: prospective cohort we investigated serial samples from 164 after mRNA (82 patients 82 healthy...